Nahon-Esteve Sacha, Martel Arnaud, Maschi Celia, Alketbi Mohamed, Baillif Stephanie, Tieulie Nathalie
Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Department of Ophthalmology, Nice, France.
Eur J Ophthalmol. 2021 Sep;31(5):2457-2466. doi: 10.1177/1120672120962066. Epub 2020 Oct 2.
To study the outcome of latent tubercular uveitis (LTBU) treated with antitubercular therapy (ATT) combined or not with adjuvant systemic corticosteroids.
Twenty patients (27 eyes) with LTBU were included in a monocentric retrospective study and evaluated for the absence of active disease after treatment. Data on the clinical outcomes (active inflammation), vision (best-corrected visual acuity, BCVA) and treatment were collected retrospectively.
Fourteen patients received ATT alone and six patients received ATT combined with systemic corticosteroids. The two groups were not comparable in terms of proportion of tubercular panuveitis cases and initial BCVA (59.3 ± 8.2 letters vs 44.2 ± 15.2 letters). There was no significant difference in remission rate and in BCVA between both groups 3 months after ATT discontinuation.
Patients with LTBU treated with ATT alone had visual and inflammatory outcomes at least comparable to those of patients treated with ATT combined with systemic corticosteroids.
研究抗结核治疗(ATT)联合或不联合辅助全身用糖皮质激素治疗潜伏性结核性葡萄膜炎(LTBU)的疗效。
20例(27只眼)LTBU患者纳入一项单中心回顾性研究,并评估治疗后无活动性疾病的情况。回顾性收集临床结局(活动性炎症)、视力(最佳矫正视力,BCVA)和治疗的数据。
14例患者仅接受ATT治疗,6例患者接受ATT联合全身用糖皮质激素治疗。两组在结核性全葡萄膜炎病例比例和初始BCVA方面不具有可比性(59.3±8.2字母对44.2±15.2字母)。停用ATT 3个月后,两组的缓解率和BCVA均无显著差异。
仅接受ATT治疗的LTBU患者的视力和炎症结局至少与接受ATT联合全身用糖皮质激素治疗的患者相当。